Who
James M. Daly
Director
Company insider
Files Form 4 as: Director, Halozyme Therapeutics; Director, Cytokinetics; Director, Madrigal Pharmaceuticals; Director, ACADIA Pharmaceuticals; Director, Bellicum Pharmaceuticals; Director, Chimerix; EVP, Chief Commercial Officer, Incyte.
In numbers
- Trades disclosed
- 264
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $44.4M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 22 Oct 2012
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,169 at $0.00 | filing |
| 1 Oct 2026filed 2 Oct 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,775 at $0.00 | filing |
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $12K151 at $82.62 | filing |
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $12K151 at $82.62 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name James M. Daly; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.